+

PE20060677A1 - Inhibidores de la arn polimerasa dependiente de arn del virus de la hepatitis c y composiciones que los contienen - Google Patents

Inhibidores de la arn polimerasa dependiente de arn del virus de la hepatitis c y composiciones que los contienen

Info

Publication number
PE20060677A1
PE20060677A1 PE2005000945A PE2005000945A PE20060677A1 PE 20060677 A1 PE20060677 A1 PE 20060677A1 PE 2005000945 A PE2005000945 A PE 2005000945A PE 2005000945 A PE2005000945 A PE 2005000945A PE 20060677 A1 PE20060677 A1 PE 20060677A1
Authority
PE
Peru
Prior art keywords
hepatitis
inhibitors
cr6r7
ethyl
heterocyclyl
Prior art date
Application number
PE2005000945A
Other languages
English (en)
Inventor
Javier Gonzalez
Tanya Michelle Jewell
Angelica Linton
John Howard Tatlock
Hui Li
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PE20060677A1 publication Critical patent/PE20060677A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/32Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyrane Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

REFERIDA A UN COMPUESTO DERIVADO DE PIRANONA DE FORMULA (4), DONDE R1 ES CICLOPENTILO; R2 ES -(CR6R7)n(HETEROCICLILO DE 5 A 6 MIEMBROS), DONDE DICHO HETEROCICLILO ESTA OPCIONALMENTE SUSTITUIDO CON AL MENOS UN GRUPO R4; R3 ES -(CR6R7)t(ARILO C6-C10) O -(CR6R7)t(HETEROCICLILO DE 4 A 10 MIEMBROS), ENTRE OTROS; R4 ES HALO, OR6, OXO, ENTRE OTROS; R5 ES ALQUILO C1-C6, HALO, OR6, ENTRE OTROS; R6 Y R7 SON H O ALQUILO C1-C6, n ES 0, 1, 2, 3, 4 O 5; t ES 0, 1, 2, 3, 4 O 5. SON COMPUESTOS PREFERIDOS: 6-[2-(6-AMINO-5-ETIL-2-METILPIRIDIN-3-IL)ETIL]-6-CICLOPENTIL-3-[(5,7-DIMETIL[1,2,4]TRIAZOLO[1,5-a]PIRIMIDIN-2-IL)METIL]-4-HIDROXI-5,6-DIHIDRO-2H-PIRAN-2-ONA, 6-CICLOPENTIL-3-[(5,7-DIMETIL[1,2,4]TRIAZOLO[1,5-a]PIRIMIDIN-2-IL)METIL]-6-[2-(4-ETILPIRIDIN-2-IL)ETIL]-4-HIDROXI-5,6-DIHIDRO-2H-PIRAN-2-ONA, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA ENZIMA POLIMERASA DEL VIRUS DE LA HEPATITIS C (HCV) Y SON UTILES EN EL TRATAMIENTO DE MAMIFEROS INFECTADOS POR HCV
PE2005000945A 2004-08-18 2005-08-15 Inhibidores de la arn polimerasa dependiente de arn del virus de la hepatitis c y composiciones que los contienen PE20060677A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US60261804P 2004-08-18 2004-08-18

Publications (1)

Publication Number Publication Date
PE20060677A1 true PE20060677A1 (es) 2006-08-11

Family

ID=35429645

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000945A PE20060677A1 (es) 2004-08-18 2005-08-15 Inhibidores de la arn polimerasa dependiente de arn del virus de la hepatitis c y composiciones que los contienen

Country Status (43)

Country Link
US (3) US7151105B2 (es)
EP (1) EP1781662B1 (es)
JP (1) JP4372195B2 (es)
KR (1) KR100851178B1 (es)
CN (2) CN101538268B (es)
AP (1) AP2313A (es)
AR (1) AR050699A1 (es)
AT (1) ATE506364T1 (es)
AU (1) AU2005273619B2 (es)
BR (1) BRPI0514425A (es)
CA (1) CA2577525C (es)
CR (2) CR8935A (es)
CY (1) CY1111480T1 (es)
DE (1) DE602005027580D1 (es)
DK (1) DK1781662T3 (es)
EA (1) EA012605B1 (es)
EC (1) ECSP077264A (es)
ES (1) ES2361845T3 (es)
GE (2) GEP20115305B (es)
GT (1) GT200500221A (es)
HK (1) HK1109617A1 (es)
HN (1) HN2005000449A (es)
HR (1) HRP20110458T1 (es)
IL (2) IL180933A (es)
MA (1) MA28803B1 (es)
MX (1) MX2007001527A (es)
MY (1) MY146123A (es)
NI (1) NI200700043A (es)
NL (1) NL1029755C2 (es)
NO (1) NO20071274L (es)
NZ (1) NZ552874A (es)
PE (1) PE20060677A1 (es)
PL (1) PL1781662T3 (es)
PT (1) PT1781662E (es)
RS (1) RS51794B (es)
SI (1) SI1781662T1 (es)
SV (1) SV2007002202A (es)
TN (1) TNSN07066A1 (es)
TW (1) TWI376379B (es)
UA (1) UA88909C2 (es)
UY (1) UY29068A1 (es)
WO (1) WO2006018725A1 (es)
ZA (1) ZA200700779B (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20115305B (en) * 2004-08-18 2011-10-10 Pfizer Inhibitors of hepatitis c virus rna-dependent rna polymerase, compositions containing them and using the same for treatment
NZ565496A (en) * 2005-08-24 2010-10-29 Pfizer Methods for the preparation of HCV polymerase inhibitors
JP2010526143A (ja) 2007-05-04 2010-07-29 バーテックス ファーマシューティカルズ インコーポレイテッド Hcv感染の処置のための併用療法
EP2008996A1 (en) * 2007-06-27 2008-12-31 Syngeta Participations AG Process for the production of pyrazoles
CN102083852A (zh) 2008-06-06 2011-06-01 西尼克斯公司 环孢菌素类似物及其在治疗hcv感染中的应用
AU2009281195A1 (en) 2008-08-11 2010-02-18 Glaxosmithkline Llc Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases
UA103195C2 (uk) 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
SI2320905T1 (sl) 2008-08-11 2017-10-30 Glaxosmithkline Llc Corporation Service Company Novi adeninski derivati
UY32940A (es) 2009-10-27 2011-05-31 Bayer Cropscience Ag Amidas sustituidas con halogenoalquilo como insecticidas y acaricidas
PH12012500827A1 (en) 2009-10-30 2013-01-07 Boehringer Ingelheim Int Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin
EP2325173A1 (de) 2009-11-19 2011-05-25 Bayer CropScience AG Verfahren zum Herstellen von 5-Fluor-1-alkyl-3-fluoralkyl-1H-pyrazol-4-carbonsäurechloriden
PH12012501216A1 (en) * 2009-12-18 2012-11-05 Boehringer Ingelheim Int Hcv combination therapy
CA2786973C (en) 2010-02-10 2018-04-10 Robert Hermann Gibbon 6-amino-2-{[(1s)-1-methylbutyl] oxy}-9-[5-(1-piperidinyl)-7,9-dihydro-8h-purin-8-one maleate
JP2013519644A (ja) 2010-02-10 2013-05-30 グラクソスミスクライン エルエルシー プリン誘導体およびそれらの薬学的使用
KR102011648B1 (ko) * 2010-05-20 2019-08-19 바이엘 크롭사이언스 악티엔게젤샤프트 1-알킬-3-디플루오르메틸-5-히드록시피라졸의 제조 방법
US8987307B2 (en) 2011-03-03 2015-03-24 Hoffmann-La Roche Inc. 3-amino-pyridines as GPBAR1 agonists
FR2972452B1 (fr) 2011-03-09 2013-03-15 Rhodia Operations Procede de preparation du difluoroacetonitrile et de ses derives
MX348274B (es) 2012-05-14 2017-06-02 Bayer Cropscience Ag Procedimiento de preparacion de cloruros de 1-alquil-3-fluoroalqui l-1h-pirazol-4-carbonilo.
WO2014081878A2 (en) 2012-11-21 2014-05-30 Stategics, Inc. Substituted triazolo-pyrimidine compounds for modulating cell proliferation, differentiation and survival
KR102261967B1 (ko) 2013-01-17 2021-06-07 바이엘 크롭사이언스 악티엔게젤샤프트 5-플루오로-1-메틸-3-디플루오로메틸-1h-피라졸-4-카브알데히드 제조 방법
BR112015018311B1 (pt) 2013-02-06 2021-01-05 Bayer Animal Health Gmbh compostos derivados de pirazol substituídos por halogêneo como agentes de controle de pragas, composição farmacêutica e uso dos mesmos, processo para a preparação de composições de proteção de colheitas e método para o controle de pragas
KR20160104065A (ko) 2014-01-03 2016-09-02 바이엘 애니멀 헬스 게엠베하 농약으로서의 신규 피라졸릴헤테로아릴아미드
DK3097081T3 (da) 2014-01-24 2018-01-29 Bayer Cropscience Ag Fremgangsmåde til fremstilling af 1-alkyl-3-difluormethyl-5-fluor-1h-pyrazol-4-carbaldehyder og 1-alkyl-3-difluormethyl-5-fluor-1h-pyrazol-4-carboxylater
WO2015124591A1 (en) 2014-02-20 2015-08-27 Glaxosmithkline Intellectual Property (No.2) Limited Pyrrolo[3,2] pyrimidine derivatives as inducers of human interferon
MA40281B1 (fr) 2014-06-03 2018-11-30 Idorsia Pharmaceuticals Ltd Composés de pyrazole et leur utilisation en tant qu' agents de blocage des canaux calciques de type t
MX2017006302A (es) 2014-11-13 2018-02-16 Glaxosmithkline Biologicals Sa Derivados de adenina que son utiles en el tratamiento de enfermedades alergicas u otras afecciones inflamatorias.
WO2017093180A1 (de) 2015-12-01 2017-06-08 Bayer Cropscience Aktiengesellschaft Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel
CR20180286A (es) 2015-12-03 2018-07-16 Glaxosmithkline Ip Dev Ltd Dinucleotidos de purina cíclicos como moduladores de sting
EP3440072B1 (en) 2016-04-07 2020-01-29 GlaxoSmithKline Intellectual Property Development Ltd Heterocyclic amides useful as protein modulators
CN109071514B (zh) 2016-04-07 2021-07-06 葛兰素史密斯克莱知识产权发展有限公司 用作蛋白质调节剂的杂环酰胺
CN109996799B (zh) 2016-08-15 2022-07-19 拜耳作物科学股份公司 作为害虫防治剂的稠合双环杂环衍生物
EP3301094A1 (en) * 2016-09-30 2018-04-04 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
KR20210065206A (ko) 2016-12-16 2021-06-03 이도르시아 파마슈티컬스 리미티드 T-유형 칼슘 채널 차단제를 포함하는 약학 조합물
MX376203B (es) 2017-02-06 2025-03-07 Idorsia Pharmaceuticals Ltd Un proceso novedoso para la sintesis de 1-aril-1-trifluoro-metil-ciclopropanos.
AU2018344370C1 (en) 2017-10-04 2023-04-27 Bayer Aktiengesellschaft Derivatives of heterocyclic compounds as pest control agents
WO2019069270A1 (en) 2017-10-05 2019-04-11 Glaxosmithkline Intellectual Property Development Limited GENERATOR STIMULATOR MODULATORS (STING) INTERFERON
TW201927771A (zh) 2017-10-05 2019-07-16 英商葛蘭素史密斯克藍智慧財產發展有限公司 可作為蛋白質調節劑之雜環醯胺及其使用方法
EP3765466B1 (de) 2018-03-12 2022-05-25 Bayer Aktiengesellschaft Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel
US20210169080A1 (en) 2018-04-20 2021-06-10 Bayer Aktiengesellschaft Heterocycle derivatives as pesticides
GB201807924D0 (en) 2018-05-16 2018-06-27 Ctxt Pty Ltd Compounds
EP3969452A1 (en) 2019-05-16 2022-03-23 Stingthera, Inc. Benzo[b][1,8]naphthyridine acetic acid derivatives and methods of use
JP2022533390A (ja) 2019-05-16 2022-07-22 スティングセラ インコーポレイテッド オキソアクリジニル酢酸誘導体および使用方法
GB201910305D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
GB201910304D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
JP7662644B2 (ja) 2019-12-18 2025-04-15 シーティーエックスティー・ピーティーワイ・リミテッド 化合物
US12274700B1 (en) 2020-10-30 2025-04-15 Accencio LLC Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors
CN112194620B (zh) * 2020-12-04 2021-02-26 苏州开元民生科技股份有限公司 一种2-乙基-4-氰基吡啶的制备方法
CN113563167B (zh) * 2021-07-16 2023-09-08 南通华祥医药科技有限公司 一种2-甲基-1-四氢萘酮的制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3786063A (en) 1971-05-24 1974-01-15 Universal Oil Prod Co Thiazolethiosulfonates
DE2155360C3 (de) * 1971-11-08 1980-04-03 Cassella Ag, 6000 Frankfurt Verfahren zur Herstellung von Acylbernsteinsäuredialkylestern
CA1144937A (en) 1977-12-22 1983-04-19 Dke J.E. Helgstrand Aromatic derivatives, pharmaceutical compositions and methods for combatting virus infections
US4326058A (en) 1979-02-05 1982-04-20 Sumitomo Chemical Company, Limited Organo-phosphoric esters and their production and use
US4489077A (en) 1983-03-23 1984-12-18 Warner-Lambert Company 3-Isoxa-zolyl-2H-1,2-benzothiazine-3-carboxamide, 1,1-dioxides
US6174868B1 (en) 1992-09-10 2001-01-16 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of hepatitis C virus-associated diseases
US5846964A (en) 1993-07-19 1998-12-08 Tokyo Tanabe Company Limited Hepatitis C virus proliferation inhibitor
US5504104A (en) 1993-11-19 1996-04-02 Warner-Lambert Company Tricyclic pyrone derivatives as protease inhibitors and antiviral agents
US5840751A (en) 1993-11-19 1998-11-24 Warner-Lambert Company 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents
US6005103A (en) 1993-11-19 1999-12-21 Warner-Lambert Company Pyrone derivatives as protease inhibitors and antiviral agents
CZ291856B6 (cs) 1993-11-19 2003-06-18 Parke, Davis & Company 5,6-Dihydropyronové deriváty jako inhibitory proteázy a protivirová činidla a farmaceutické kompozice obsahující tyto deriváty
ES2219457T3 (es) 1993-11-19 2004-12-01 PARKE, DAVIS & COMPANY Derivados de 5,6-dihidropironas como inhibidores de proteasa y agentes antiviricos.
US5834506A (en) * 1996-11-01 1998-11-10 Warner-Lambert Company Dihydropyrones with improved antiviral activity
EP1112269A2 (en) 1998-09-11 2001-07-04 Warner-Lambert Company Hiv protease inhibitors
US6512006B1 (en) 1999-12-09 2003-01-28 Warner-Lambert Company HIV protease inhibitors
EP1256628A3 (en) 2001-05-10 2003-03-19 Agouron Pharmaceuticals, Inc. Hepatitis c virus (hcv) ns5b rna polymerase and mutants thereof
DOP2003000641A (es) 2002-05-10 2003-11-15 Pfizer Inhibidores de las arn polimerasa dependiente de arn del virus de las hepatitis c y composiciones y tratamiento que los usan
US7148226B2 (en) * 2003-02-21 2006-12-12 Agouron Pharmaceuticals, Inc. Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
GEP20115305B (en) * 2004-08-18 2011-10-10 Pfizer Inhibitors of hepatitis c virus rna-dependent rna polymerase, compositions containing them and using the same for treatment

Also Published As

Publication number Publication date
NI200700043A (es) 2008-01-02
UA88909C2 (ru) 2009-12-10
GEP20094751B (en) 2009-08-10
BRPI0514425A (pt) 2008-06-10
IL192919A0 (en) 2009-02-11
KR20070044057A (ko) 2007-04-26
ES2361845T3 (es) 2011-06-22
EP1781662A1 (en) 2007-05-09
MA28803B1 (fr) 2007-08-01
EA200700338A1 (ru) 2007-08-31
US20060122399A1 (en) 2006-06-08
WO2006018725A1 (en) 2006-02-23
HRP20110458T1 (hr) 2011-07-31
JP2008509984A (ja) 2008-04-03
AP2313A (en) 2011-10-31
GEP20115305B (en) 2011-10-10
CN101006092B (zh) 2013-04-17
GT200500221A (es) 2006-06-21
CR20110153A (es) 2011-04-26
US20070015764A1 (en) 2007-01-18
US7622605B2 (en) 2009-11-24
AU2005273619A1 (en) 2006-02-23
NL1029755C2 (nl) 2006-10-18
TW200612898A (en) 2006-05-01
AR050699A1 (es) 2006-11-15
DK1781662T3 (da) 2011-06-27
NL1029755A1 (nl) 2006-02-21
DE602005027580D1 (de) 2011-06-01
KR100851178B1 (ko) 2008-08-08
SV2007002202A (es) 2007-03-20
US20090281122A1 (en) 2009-11-12
AU2005273619B2 (en) 2009-05-28
CY1111480T1 (el) 2015-08-05
NZ552874A (en) 2010-04-30
PT1781662E (pt) 2011-07-01
RS51794B (en) 2011-12-31
HN2005000449A (es) 2009-10-30
ATE506364T1 (de) 2011-05-15
PL1781662T3 (pl) 2011-08-31
MX2007001527A (es) 2007-03-27
IL180933A (en) 2011-08-31
CA2577525C (en) 2010-03-30
IL180933A0 (en) 2007-07-04
CA2577525A1 (en) 2006-02-23
TWI376379B (en) 2012-11-11
TNSN07066A1 (fr) 2008-06-02
CR8935A (es) 2007-07-24
EP1781662B1 (en) 2011-04-20
SI1781662T1 (sl) 2011-07-29
HK1109617A1 (en) 2008-06-13
MY146123A (en) 2012-06-29
CN101538268B (zh) 2011-07-27
ZA200700779B (en) 2008-11-26
EA012605B1 (ru) 2009-10-30
US8268835B2 (en) 2012-09-18
US7151105B2 (en) 2006-12-19
UY29068A1 (es) 2006-03-31
CN101538268A (zh) 2009-09-23
CN101006092A (zh) 2007-07-25
NO20071274L (no) 2007-05-14
JP4372195B2 (ja) 2009-11-25
AP2007003918A0 (en) 2007-02-28
ECSP077264A (es) 2007-04-26

Similar Documents

Publication Publication Date Title
PE20060677A1 (es) Inhibidores de la arn polimerasa dependiente de arn del virus de la hepatitis c y composiciones que los contienen
PE20060381A1 (es) Analogos de dipeptidos inhibidores de la hepatitis c
PE20121479A1 (es) Inhibidores del virus de la hepatitis c
ECSP066780A (es) Inhibidores de polimerasa viral
UY28323A1 (es) Compuestos inhibidores de la hepatitis c
PE20091381A1 (es) Inhibidores del virus de la hepatitis c
PE20081658A1 (es) Derivados indolicos con anillo unido en las posiciones 5,6 y sus metodos de uso
EA200701849A1 (ru) Пролекарственные соединения трициклических нуклеозидов, фармацевтическая композиция на их основе и способ лечения и/или ингибирования вирусной инфекции у млекопитающего
PE20160858A1 (es) Analogos carba-nucleosidicos para tratamiento antiviral
PE20090648A1 (es) Compuestos para el tratamiento de la hepatitis c
ECSP077171A (es) Inhibidores de polimerasa viral
EA200300819A1 (ru) Производные нуклеозидов в качестве ингибиторов рнк-зависимой рнк вирусной полимеразы
PE20080070A1 (es) Derivados de indolobenzazepina fusionados a ciclopropilo como inhibidores de la polimerasa ns5b del virus de la hepatitis c
PE20050289A1 (es) Inhbidores de la arn polimerasa dependientes de arn del virus de la hepatitis c y composiciones y tratamiento que los usan
ATE389656T1 (de) Pyrazolo(1,5-a)pyrimidin-verbindungen als antivirale agentien
GT200600262A (es) Uso de la sangliferina en el hcv (virus de la hepatitis "c")
UY28582A1 (es) Métodos para preparar derivados 7-(b (beta)-d-ribofuranosilo sustituido en 2´)-4(nr2r3)-5-(etin-1-ilo sustituido) -pirrol(2,3-d) pirimidina
BR0305259A (pt) Inibidores de hcv ns5b polimerase
PE20040472A1 (es) Composiciones inhibidoras de la arn polimerasa dependiente de arn del virus de la hepatitis c
ATE432922T1 (de) Substituierte 5-carboxyamidpyrazoles und ä1,2, 4ütriazole als viruzide
PE20081113A1 (es) Inhibidores virales policiclicos
PE20220252A1 (es) Compuestos de pirrol
ATE498398T1 (de) Cycloalkyl-heterozyklen zur behandlung des hepatitis-c-virus
DE602007011213D1 (de) Heterocyclische antivirale verbindungen
GT200300239A (es) Compuestos de benzofurano, composiciones y metodos para tratamiento y profilaxis de infecciones virales de hepatitis c y enfermedades asociadas

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed
点击 这是indexloc提供的php浏览器服务,不要输入任何密码和下载